Minerva Neurosciences (Minerva Neurosciences) Change In Working Capital : $4.94 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences Change In Working Capital?

Minerva Neurosciences's change in working capital for the quarter that ended in Dec. 2023 was $0.22 Mil.

Minerva Neurosciences's change in working capital for the fiscal year that ended in Dec. 2023 was $4.94 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Minerva Neurosciences Change In Working Capital Historical Data

The historical data trend for Minerva Neurosciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences Change In Working Capital Chart

Minerva Neurosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

3.44

-45.56

0.26

-4.06

4.94

Minerva Neurosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-0.26	4.49	-0.33	0.55	0.22

Minerva Neurosciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.94 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Minerva Neurosciences Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Minerva Neurosciences (Minerva Neurosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

4MNA:Germany 4MNA:Germany

Address

1500 District Avenue, Burlington, MA, USA, 01803

Website

https://www.minervaneurosciences.com

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Executives

Ag Boehringer	10 percent owner	BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh	10 percent owner	200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer	officer: EVP and Head of R&D	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race	officer: EVP and CFO	C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm	officer: Chief Accounting Officer	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer	director	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly	officer: Chief Business Officer	C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell	officer: President	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle	director
Hans Peter Hasler	director	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd	10 percent owner	5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd	10 percent owner	44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG